Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 27121-27130 Newer>

The Motley Fool November 6, 2007 Rick Aristotle Munarriz	XM + Sirius = Patience The FCC may be ready to give its blessing to the satellite radio merger. Investors, take note.
The Motley Fool November 6, 2007 Ron Vlieger	IP Not Looking Good on Paper International Paper's latest quarter suggests that its makeover is still a work in progress. Investors, take note.
The Motley Fool November 6, 2007 Anders Bylund	Fool on Call: Action, Not Drama, at Blockbuster Investors should like Blockbuster's new CEO. Keyes cleared up plenty of outstanding issues in the company's most recent earnings call.
The Motley Fool November 6, 2007 Dave Mock	Foolish Forecast: j2 Global's Growing Moat The Internet fax and messaging service provider is set to report its third-quarter earnings results. Investors, here is what you can expect to see.
The Motley Fool November 6, 2007 Anders Bylund	The Sun Is the Same, in a Relative Way: Fool by Numbers The data center conqueror released first-quarter 2008 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool November 6, 2007 Brian Lawler	It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results.
The Motley Fool November 6, 2007 Tom Taulli	Dell in the M&A Fast Lane The PC maker is getting deeper into the world of data storage. Investors, take note.
The Motley Fool November 6, 2007 Rick Aristotle Munarriz	Diller's Banana Split Within the next few months the InterActiveCorp media empire will be split into five distinct companies: IAC... Ticketmaster... HSN... LendingTree... and Interval International...
The Motley Fool November 6, 2007 Saibal Saha	The Power of Global Brands Corporate brands provide tremendous marketing leverage, however, a company that has a lot riding on its brand runs the risk that one unfavorable issue will affect the entire business. There are pros and cons to this strategy.
The Motley Fool November 6, 2007 Brian Lawler	The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good.
<Older 27121-27130 Newer> Return to current articles.